Sign in

    Yen-Der Li

    Senior Equity Research Analyst at Leerink Partners

    Yen-Der Li, M.D., Ph.D., is a Senior Equity Research Analyst at Leerink Partners specializing in genetic medicine and emerging oncology, with coverage of companies including Adaptimmune Therapeutics, Bicycle Therapeutics, Genmab, Arcturus Therapeutics, Sensorion SA, and Voyager Therapeutics. Renowned for his depth in biopharmaceutical analysis, Li's research supports market ratings and detailed forecasts, contributing to Leerink's sector-leading performance in biotech equities. He began his analyst career after earning dual doctoral degrees, and has become a recognized expert in genetic medicine since joining Leerink Partners in the early 2020s. Li holds medical and doctoral credentials and maintains professional securities licenses aligned with FINRA standards.

    Yen-Der Li's questions to Nanobiotix (NBTX) leadership

    Yen-Der Li's questions to Nanobiotix (NBTX) leadership • FY 2024

    Question

    Yen-Der Li of Leerink Partners inquired about the timeline for initial data from the J&J-led Phase II CONVERGE study in lung cancer and the factors supporting confidence in its success. He also asked how the upcoming pancreatic cancer data presentation will differ from last year's press release and what the subsequent steps would be for NBTXR3 in that indication.

    Answer

    Co-Founder and CEO Laurent Levy explained that while a specific data timeline for the CONVERGE study cannot be shared yet, confidence is high due to NBTXR3's consistent ability to improve local tumor control. Regarding the pancreatic cancer data, Levy stated the full dataset, including efficacy, safety, and potential biomarkers, will be presented, going beyond the top-line survival data previously released. He added that the next step, a new cohort adding chemotherapy to the treatment regimen, is already recruiting patients.

    Ask Fintool Equity Research AI

    Yen-Der Li's questions to Kura Oncology (KURA) leadership

    Yen-Der Li's questions to Kura Oncology (KURA) leadership • Q4 2024

    Question

    Yen-Der Li, on behalf of Jonathan Chang at Leerink Partners, asked about the company's confidence in achieving a long treatment duration for ziftomenib in frontline AML. He also questioned the protocol for mitigating potential imbalances in consolidation treatments within the KOMET-017 trial.

    Answer

    CMO Dr. Mollie Leoni cited data from the KOMET-007 trial showing prolonged use of ziftomenib, which informed their confidence. CCO Brian Powl added that an 18-24 month duration supports a potential $7 billion market. Dr. Leoni also explained the KOMET-017 trial is designed and powered with sensitivity analyses to account for any treatment imbalances between arms.

    Ask Fintool Equity Research AI

    Yen-Der Li's questions to Mersana Therapeutics (MRSN) leadership

    Yen-Der Li's questions to Mersana Therapeutics (MRSN) leadership • Q3 2024

    Question

    Yen-Der Li from Leerink Partners inquired about the expected number of efficacy-evaluable and biomarker-positive patients for the initial XMT-1660 data update, and also asked for insights on the performance of more frequent dosing cohorts.

    Answer

    CEO Martin Huber stated that specific patient numbers and B7-H4 expression data would be disclosed at the year-end data event. He clarified that B7-H4 data is collected retrospectively and may be incomplete for some patients at disclosure. Regarding dosing, Dr. Huber confirmed the every-4-week schedule is being escalated but declined to share comparative data on more frequent dosing schedules, noting that dose-activity relationships will be part of the future data release.

    Ask Fintool Equity Research AI